There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Catalent (CTLT – Research Report), Vertex Pharmaceuticals (VRTX – Research Report) and Alkermes (ALKS – Research Report) with bullish sentiments.
Catalent (CTLT)
In a report issued on April 9, Eric Coldwell from Robert W. Baird maintained a Buy rating on Catalent, with a price target of $63.50. The company’s shares closed last Thursday at $56.92.
According to TipRanks.com, Coldwell is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Catalent with a $60.75 average price target.
See the top stocks recommended by analysts >>
Vertex Pharmaceuticals (VRTX)
In a report released yesterday, David Risinger from Leerink Partners maintained a Buy rating on Vertex Pharmaceuticals. The company’s shares closed last Thursday at $400.23.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $455.29 average price target, which is a 12.6% upside from current levels. In a report released yesterday, William Blair also initiated coverage with a Buy rating on the stock.
Alkermes (ALKS)
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes on April 9 and set a price target of $37.00. The company’s shares closed last Thursday at $24.99.
According to TipRanks.com, Beatty is a 5-star analyst with an average return of
Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $35.75, which is a 35.9% upside from current levels. In a report issued on April 2, Mizuho Securities also maintained a Buy rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTLT:
- Piper Sandler healthcare/pharma analysts hold analyst/industry conference call
- William Blair healthcare analysts hold analyst/industry conference call
- A New Cause for Concern: Catalent Inc Adds a New Share Price & Shareholder Rights Risk
- Catalent to delay 10-Q filing
- Catalent price target raised to $63.50 from $56 at Baird
